Stocktoria
Aclaris Therapeutics, Inc. ACRS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-10-07
Aclaris Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $7.8M | $18.7M | $31.2M | $29.8M | $6.8M |
| R&D expense | $52.6M | $33.6M | $98.4M | $77.8M | $43.8M |
| Operating income | -$76.4M | -$141.9M | -$97.4M | -$89.9M | -$89.7M |
| Income tax | — | — | -$367,000 | — | — |
| Net income | -$64.9M | -$132.1M | -$88.5M | -$86.9M | -$90.9M |
| EPS (diluted) | $-0.53 | $-1.71 | $-1.27 | $-1.33 | $-1.60 |
| Operating cash flow | -$47.1M | -$20.1M | -$78.3M | -$67.6M | -$52.1M |
| Free cash flow | -$47.2M | -$20.2M | -$79.6M | -$68.2M | -$52.4M |
| Cash & equivalents | $20.0M | $24.6M | $39.9M | $45.3M | $27.3M |
| Total assets | $160.5M | $220.3M | $197.4M | $254.6M | $251.2M |
| Total liabilities | $57.4M | $64.8M | $40.2M | $57.0M | $53.9M |
| Shareholders' equity | $103.1M | $155.6M | $157.2M | $197.6M | $197.3M |
Source: SEC EDGAR filings · CIK 0001557746 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.